Vitro Diagnostics Inc. (fka VODG)

[Potse]

VODG(.12)...license agreement expected......

There could be a number of potentially interesting developments and press releases coming from VODG in calendar 2011. If the competitive advantages of its VitroGrow culture media are as distinct as indicated, it is probably only a matter of time before the product begins to gain much more significant traction in the market. And the indications coming from the last 10-Q and 10-K suggest the fertility drug technology is now back in play with an expectation of a license agreement being signed in 2011.

VitroGrow: An item from the 10-K filed on Friday, pertaining to the VitroGrow product line.....

The Company believes it has significant prospective sales opportunities that management is pursuing to the full extent possible. These efforts have been bolstered by a recently completed Company study showing performance advantages of its VitroGrow™ Brand of stem cell media over major leaders of this market segment. We plan to leverage the competitive advantages of our VitroGrow™ product line into significant penetration of this market through alliances with major distributors of life science products. The Company is engaged in discussions with prospective partners and intends to pursue development of these business relations to the full extent possible. These potential partners possess manufacturing capabilities and well-established, global distribution channels, but lack product offerings that are equivalent to the VitroGrow™ stem cell media product line

Fertility Drug Technology: Based on language in the last 10-Q and the 10-K, it appears VODG is very close to entering into a license agreement for its fertility drug technology. From the 10-Q filed in September.....

Management is engaged with numerous current and prospective customers regarding product sales and there are several opportunities for collaboration with other firms and university researchers working in the stem cell sector that may lead to strategic alliances further expanding sales of the Company’s products and development of new products targeting stem cell research and drug development. Also, there is renewed interest by an offshore third party in commercialization of the Company’s fertility drug product and technology portfolio.

And now two items from the 10-K, which strongly suggest progress is being made toward a license agreement......

The Company's previous manufacture and sale of purified antigens for diagnostic purposes resulted in the discovery of several products and technologies with potential application for therapeutic purposes. An initial target was the pituitary hormone FSH and related products, since FSH has been used as a drug to treat infertility for the past 35 years. The worldwide market for FSH and related products is approximately $1.3 billion per year. However, in the recent past, the Company has utilized its limited resources for its stem cell research in an effort to establish financial support and revenue from product sales in the near term. During 2010, we began negotiations for out-licensing of our patented technology related to FSH manufacture. We anticipate establishment of a license agreement in the near future. We may also provide the licensee with assistance in sourcing necessary raw materials, distribution of finished product and options to advanced stem-cell based methods for FSH production. The Company's stem cell technology has potential application to generation of new cell lines for FSH production but this development would require additional R&D to demonstrate feasibility.

Management anticipates substantially larger increases in revenue during fiscal year 2011 due to a shifted focus to the establishment of distribution agreements for sales of VitroGrow™ Media as described in greater detail in Section 1 and out-licensing of its patented and patent-pending technology related to treatment of infertility.